Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This World Cancer Day, we heard from four Group Leaders at the MRC Weatherall Institute of Molecular Medicine about their work and how their groups are helping in the fight against cancer.

Professor KJ Patel is the Chief Scientist of Cancer Research UK, as well as the Director of both the MRC WIMM and the MRC Molecular Haematology Unit (MRC MHU). The Patel Group are investigating how alcohol can contribute to the emergence of a number of common cancers.

Andi Roy is a Professor of Paediatric Haematology in the Department of Paediatrics and a member of the MRC MHU. She is also an honorary paediatric haematology consultant at Great Ormond Street Hospital in London. Professor Roy leads her group in the study of childhood leukaemia, specifically blood cancers, and how they develop early in life.

Ahmed Ahmed is a Professor of Gynaecological Oncology in the Nuffield Department of Women’s Reproductive Health and a consultant surgeon at the Oxford Cancer and Haematology Centre. The Ahmed Group is looking into how normal cells develop into cancer cells, with the aim of improving early detection of ovarian cancers. 

Ben Fairfax is a Professor of Cancer Immunogenetics in the Department of Oncology, in addition to being an honorary consultant oncologist with the Oxford University Hospitals. His group researches how genetics can influence how well patients respond to cancer immunotherapy. 

 

This video highlights just some of the amazing research being carried out by MRC WIMM researchers in this field.

 

The research mentioned in this video was funded by the Medical Research Council, Cancer Research UK, the Wellcome Trust, Ovarian Cancer Action and the NIHR Oxford Biomedical Research Centre.

Recent stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.